NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress...
SANTA ANA, Calif., October 17, 2023 — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Announces Poster Presentation at the 16th Annual Clinical...
SANTA ANA, Calif., October 19, 2023 — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Announces FDA Clearance of Investigational New Drug Application...
NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023 NKGen’s SNK01 program continues to show positive progress in...
View ArticleNKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual...
90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer’s disease composite score (ADCOMS) following 11 weeks SNK01 given intravenously (IV) appears to cross...
View ArticleNKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business...
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease, expect to initiate Phase I/IIa by year end – SNK02...
View ArticleNKGen Biotech Announces Clearance of Clinical Trial Application by Health...
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s...
View ArticleNKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial...
NKGen Biotech’s autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease (“AD”) in its Phase 1...
View ArticleNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease...
SANTA ANA, Calif., March 4, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s...
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The additional Phase 1 SNK01 trial data suggest...
View ArticleNKGen Biotech Secures Additional Financing of $5 Million to Continue...
The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation. Additional...
View ArticleNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in...
SANTA ANA, Calif., April 18, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Announces Upcoming Publication at the 2024 American Society of...
SANTA ANA, Calif., April 24, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative...
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating...
View ArticleNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND)...
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson’s disease. The Company expects to initiate a Phase 1...
View ArticleNKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy...
SANTA ANA, Calif., May 16 , 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial...
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company...
View ArticleNKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic...
SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall...
View ArticleNKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell...
SANTA ANA, Calif., June 3, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell...
SANTA ANA, Calif., June 12, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
SANTA ANA, Calif., July 15, 2024 — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View Article